| abstract |
Novel substituted N-heterocyclyl-1-aryloxyalkyl-4-piperidineamines of formula (I), wherein each of R1 to R4, which are the same or different, is hydrogen, optionally branched C1-4 alkyl, optionally branched C1-4 alkyloxy, a halo grouping, a nitro grouping, a hydroxy grouping or a trifluoromethyl or trifluoromethoxyl grouping; R5 is hydrogen, optionally branched C1-6 alkyl, optionally branched C7-12 phenylalkyl optionally substituted on the aromatic by one or more radicals having the same definition as R1; W and X are oxygen or sulphur; Y is a C2-6 polymethylene grouping or a radical -CH2-CH(OH)-CH2-; and n is 0 or 1, are disclosed. Pure R or S isomers of said compounds, where applicable, as well as mixtures thereof, are also disclosed. Furthermore, therapeutically acceptable organic or inorganic salts of the compounds of general formula (I), and any hydrates thereof, are disclosed. Finally, a method for preparing the claimed compounds, and their use as drugs, useful in cerebral ischemia, strokes, transitory ischemic attacks and neurodegenerative diseases, are disclosed. |